Cancer Treatment Centers of America
(888) 552-6760

Have questions? Call (888) 552-6760 to speak to a cancer information specialist.

Tumor molecular profiling

What is tumor molecular profiling?

Our goal is to develop a cancer treatment plan personalized to your needs. Prior to delivering chemotherapy, we may perform tumor molecular profiling to identify chemotherapy drugs and other targeted therapies that are appropriate for your specific cancer.

By choosing personalized drugs, we strive to avoid unnecessary toxicity to you and target cancer cells as aggressively as possible from the start.

Our oncologists use tumor molecular profiling to:

  • Identify the unique molecular “blueprint” of each patient’s tumor.
  • Choose cancer treatments that are more likely to have a positive outcome and rule out those that are unlikely to be beneficial, on an individual patient basis – reducing trial and error.
  • Discover potentially beneficial treatment options that may not have been considered in an initial treatment plan.

How it works

Every cancer cell has its own pattern of active genes and proteins. Molecular profiling tests for a variety of biomarkers in the DNA of a tissue sample to help us better diagnose, stage and treat cancer on an individualized basis.

We use FoundationOne® molecular profiling, a comprehensive tumor analysis test that matches therapies to your specific biomarker information to develop an evidence-based treatment plan.

If you have a solid tumor, we’ll try to get a sample of tissue during a biopsy or surgery. Then, we’ll test for the presence of a variety of enzymes, proteins and genes to identify which therapies are likely to have a positive effect.

By comparing the tumor's information with data from thousands of clinical cancer research studies, the test identifies which treatments are likely to help and which treatments are not likely to help. This provides us with more and better information to develop a personalized treatment plan for you.

Candidates for tumor molecular profiling include:

  • Patients with solid tumors.
  • Patients with highly aggressive cancers that may not respond or have not responded to standard of care therapies.
  • Patients with rare tumor types.